All News
Lupus Linked With Greater Risk of Cardiovascular Complications of Childbirth
Pregnant women with systemic lupus erythematosus (SLE) were more prone to cardiovascular complications during delivery, and their risk seems to have increased over the past 15 years, according to national administrative data.
Read Article
Rheum Manpower Needs - More Programs! (12.2.2022)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Read Article
Rheum Drugs & IDSA Guidelines to Treat COVID-19
The Infectious Diseases Society of America has recently updated its recommendations with regards to the treatment of severely ill, hospitalized COVID-19 infected patients and also about the appropriate use of anti-IL-6, JAKs and colchicine.
Read Article
AI Future of Sacroiliitis Assessment
Dr. Rachel Tate ( @uptoTate) speaks with Dr. Fabian Proft about Abstract 0383 at #ACR22 Convergence.
https://t.co/pfeW4iQBLq https://t.co/0lFx6CpWCx
Links:
Dr. John Cush RheumNow ( View Tweet)
Can I stop Methotrexate in RA?
Dr. Pope and Dr. Meng discuss Abstract 0916 at #ACR22.
https://t.co/0hK5kNHlrS https://t.co/AXJija7Yzo
Links:
Dr. John Cush RheumNow ( View Tweet)
Remibrutinib in Sjogren's Syndrome
Dr. Putman reports on abstract 1113 presented at #ACR22 Convergence Abstract 1113: Remibrutinib (LOU064) in Sjögren’s Syndrome: Safety and Efficacy Results from a 24‑Week Placebo-controlled Proof-of-Concept Study
https://t.co/ymFkNWPaXo https://t.co/0k6vLIu0Ku
Links:
Dr. John Cush RheumNow ( View Tweet)
Rheum Drugs & IDSA Guidelines to Treat COVID-19
https://t.co/39wTAKW83E https://t.co/ir1x66FSQ8
Links:
Dr. John Cush RheumNow ( View Tweet)
RECITAL Trial: RTX vs. CTX in CTD-ILD
A UK study suggests the equivalent outcomes when patients with ILD associated with CTD are treated with either intravenous RTX or CTX, but with fewer adverse events with RTX.
https://t.co/5yaPDaw8pZ https://t.co/kcKLkIv1bK
Links:
Dr. John Cush RheumNow ( View Tweet)
Recent CDC/MMWR report shows Paxlovid x 5days (including those w/ prior COVID or vaccination), had a 51% lower hospitalization rate within 30 days after diagnosis than those not prescribed Paxlovid. Use it irrespective of vaccination status https://t.co/CBc1VBSDFR https://t.co/EC8QGaFrb3
Links:
Dr. John Cush RheumNow ( View Tweet)
Future therapy? Nanoparticles laced with rapamycin to nanoparticle stimulate regulatory T cells to suppress autoimmune disease (tested in a mouse model). https://t.co/JHFh82siff https://t.co/Y8itPXiPho
Links:
Dr. John Cush RheumNow ( View Tweet)
Impressive free read and review of Neutrophils and Netosis in Autoimmune and Autoinflammatory disorders (Nature Reviews) from Kapland & Wigerblad at the NIH. https://t.co/w4cIwcQMkt https://t.co/ReA9xM2X4j
Dr. John Cush RheumNow ( View Tweet)
Topic Podcasts - Lupus Part2
#ACR22 Daily Recap: Saturday Recap New Treatments for SLE?
https://t.co/uRI3Q3eI6E https://t.co/wBXfXw7z8J
Links:
Dr. John Cush RheumNow ( View Tweet)
Just Can’t Get Enough of Hydroxychloroquine
Several studies on HCQ dosing were presented in the poster and abstract sessions. HCQ has numerous benefits backed by evidence and unless absolutely contraindicated, patients should be maintained on it. Yet...
https://t.co/n8drUDDDjh https://t.co/AIoV3s2VhJ
Links:
Dr. John Cush RheumNow ( View Tweet)
Steroid injections worsen knee arthritis
Two studies comparing injections commonly used to relieve the pain of knee osteoarthritis found that corticosteroid injections were associated with the progression of the disease.
https://t.co/v7cDBKfM9c https://t.co/sbJ1ro0orW
Links:
Dr. John Cush RheumNow ( View Tweet)
Low Dose IL-2 Therapy in Sjögren’s
There is a large, unmet need in treating Sjögren’s syndrome, yet a new randomized clinical trial has shown that lLD-IL-2 was effective and well tolerated in patients with pSS, with evidence of restored immune balance.
https://t.co/0obaV0wnGX https://t.co/vgy91cYYvp
Links:
Dr. John Cush RheumNow ( View Tweet)
Topic Podcasts - Lupus Part1
-A Novel Treatment Response Measurement Tool for Lupus
-Breakthrough COVID infection in SLE during Omicron era
Effect of voclosporin in class V lupus nephritis
and more.
https://t.co/RVhpZtoo6b https://t.co/jjOZbLZN9m
Links:
Dr. John Cush RheumNow ( View Tweet)
Pre-RA Pharmacological Interventions: Delaying is not Enough
Dr. Aurelie Najm reports on both the Great Debate as well as abstracts 0530, 1603 at #ACR22
https://t.co/n8hzJMpmWO https://t.co/8OISSK34No
Links:
Dr. John Cush RheumNow ( View Tweet)
The complexity of opioid use in spondyloarthritis
A few things we know about opioids: use is common; it’s not efficacious in the treatment of spondyloarthritis; and, there is an opioid epidemic and its users are stigmatized.
https://t.co/B4Q7Af7doF https://t.co/sdjHoa8shP
Links:
Dr. John Cush RheumNow ( View Tweet)
ACR22: Polymyalgia Rheumatica in the Spotlight
One of the enduring legacies of #ACR22 for Dr. Putman ( @EBRheum) will be the emphasis on PMR. Despite being highly inflammatory and relatively common, a remarkable paucity of trials have been run.
https://t.co/SYKT3a03Tc https://t.co/9CIRp66vSK
Links:
Dr. John Cush RheumNow ( View Tweet)
Estimated Global SLE market size was $1.46 billion in 2020, with a global (7 Major countries) prevalence of 651,965 in 2020; and a USA prevalence of 351,176 SLE cases. https://t.co/f4Tghup5PC https://t.co/p1w9KFQR4z
Links:
Dr. John Cush RheumNow ( View Tweet)
